These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 22845494)

  • 1. Pain relief and tolerability balance of immediate release tapentadol or oxycodone treatment for patients with moderate to severe osteoarthritis or low back pain.
    Kavanagh S; Kwong WJ; Hammond GC; Nelson W; Upmalis D; Yang M
    Pain Med; 2012 Sep; 13(9):1110-20. PubMed ID: 22845494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study.
    Hartrick C; Van Hove I; Stegmann JU; Oh C; Upmalis D
    Clin Ther; 2009 Feb; 31(2):260-71. PubMed ID: 19302899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tapentadol immediate release versus oxycodone immediate release for treatment of acute low back pain.
    Biondi D; Xiang J; Benson C; Etropolski M; Moskovitz B; Rauschkolb C
    Pain Physician; 2013; 16(3):E237-46. PubMed ID: 23703422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Composite measure to assess efficacy/gastrointestinal tolerability of tapentadol ER versus oxycodone CR for chronic pain: pooled analysis of randomized studies.
    Merchant S; Provenzano D; Mody S; Ho KF; Etropolski M
    J Opioid Manag; 2013; 9(1):51-61. PubMed ID: 23709304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain.
    Daniels S; Casson E; Stegmann JU; Oh C; Okamoto A; Rauschkolb C; Upmalis D
    Curr Med Res Opin; 2009 Jun; 25(6):1551-61. PubMed ID: 19445652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bowel function after tapentadol and oxycodone immediate release (IR) treatment in patients with low back or osteoarthritis pain.
    Kwong WJ; Hammond G; Upmalis D; Okamoto A; Yang M; Kavanagh S
    Clin J Pain; 2013 Aug; 29(8):664-72. PubMed ID: 23835764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study.
    Hale M; Upmalis D; Okamoto A; Lange C; Rauschkolb C
    Curr Med Res Opin; 2009 May; 25(5):1095-104. PubMed ID: 19301989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride.
    Etropolski M; Kelly K; Okamoto A; Rauschkolb C
    Adv Ther; 2011 May; 28(5):401-17. PubMed ID: 21494892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and tolerability of tapentadol extended release in moderate to severe chronic osteoarthritis or low back pain management: pooled analysis of randomized controlled trials.
    Etropolski M; Kuperwasser B; Flügel M; Häufel T; Lange B; Rauschkolb C; Laschewski F
    Adv Ther; 2014 Jun; 31(6):604-20. PubMed ID: 24985410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose conversion between tapentadol immediate and extended release for low back pain.
    Etropolski MS; Okamoto A; Shapiro DY; Rauschkolb C
    Pain Physician; 2010; 13(1):61-70. PubMed ID: 20119464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of study discontinuations with tapentadol inmmediate release and oxycodone immediate release in patients with low back or osteoarthritis pain.
    Vorsanger G; Xiang J; Okamoto A; Upmalis D; Moskovitz B
    J Opioid Manag; 2010; 6(3):169-79. PubMed ID: 20642246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability and efficacy of tapentadol extended release in elderly patients ≥ 75 years of age with chronic osteoarthritis knee or low back pain.
    Biondi DM; Xiang J; Etropolski M; Moskovitz B
    J Opioid Manag; 2015; 11(5):393-403. PubMed ID: 26535967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of tapentadol ER for managing moderate to severe chronic pain.
    Afilalo M; Morlion B
    Pain Physician; 2013 Jan; 16(1):27-40. PubMed ID: 23340531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immediate-release tapentadol or oxycodone for treatment of acute postoperative pain after elective arthroscopic shoulder surgery: a randomized, phase IIIb study.
    Vorsanger GJ; Klopfer AM; Xiang J; Benson CJ; Moskovitz BL; Rosenthal NR
    J Opioid Manag; 2013; 9(4):281-90. PubMed ID: 24353022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post hoc analyses of data from a 90-day clinical trial evaluating the tolerability and efficacy of tapentadol immediate release and oxycodone immediate release for the relief of moderate to severe pain in elderly and nonelderly patients.
    Vorsanger G; Xiang J; Biondi D; Upmalis D; Delfgaauw J; Allard R; Moskovitz B
    Pain Res Manag; 2011; 16(4):245-51. PubMed ID: 22059194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study.
    Buynak R; Shapiro DY; Okamoto A; Van Hove I; Rauschkolb C; Steup A; Lange B; Lange C; Etropolski M
    Expert Opin Pharmacother; 2010 Aug; 11(11):1787-804. PubMed ID: 20578811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study.
    Steigerwald I; Müller M; Davies A; Samper D; Sabatowski R; Baron R; Rozenberg S; Szczepanska-Szerej A; Gatti A; Kress HG
    Curr Med Res Opin; 2012 Jun; 28(6):911-36. PubMed ID: 22443293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tapentadol immediate release for the relief of moderate-to-severe acute pain.
    Hartrick CT
    Expert Opin Pharmacother; 2009 Nov; 10(16):2687-96. PubMed ID: 19795998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pooled analysis of patient-specific factors and efficacy and tolerability of tapentadol extended release treatment for moderate to severe chronic pain.
    Etropolski M; Lange B; Goldberg J; Steup A; Rauschkolb C
    J Opioid Manag; 2013; 9(5):343-56. PubMed ID: 24353047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study.
    Gálvez R; Schäfer M; Hans G; Falke D; Steigerwald I
    Adv Ther; 2013 Mar; 30(3):229-59. PubMed ID: 23475406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.